Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Abeona Therapeutics (ABEO)

Abeona Therapeutics (ABEO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 24,688
  • Shares Outstanding, K 146,950
  • Annual Sales, $ 3,000 K
  • Annual Income, $ -84,940 K
  • 60-Month Beta 1.50
  • Price/Sales 7.55
  • Price/Cash Flow N/A
  • Price/Book 0.72
Trade ABEO with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.56
  • Most Recent Earnings -0.10 on 05/13/22
  • Next Earnings Date 05/17/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 954.48% ( -102.12%)
  • Historical Volatility 98.71%
  • IV Percentile 95%
  • IV Rank 69.15%
  • IV High 1,334.47% on 02/10/22
  • IV Low 102.83% on 06/03/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 33
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 5,323
  • Open Int (30-Day) 5,574

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.05
  • Number of Estimates 1
  • High Estimate -0.05
  • Low Estimate -0.05
  • Prior Year -0.16
  • Growth Rate Est. (year over year) +68.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1303 +28.93%
on 05/11/22
0.2414 -30.41%
on 05/03/22
-0.0520 (-23.64%)
since 04/27/22
3-Month
0.1303 +28.93%
on 05/11/22
0.3742 -55.10%
on 04/05/22
-0.0859 (-33.83%)
since 02/25/22
52-Week
0.1303 +28.93%
on 05/11/22
1.9200 -91.25%
on 06/03/21
-1.4820 (-89.82%)
since 05/27/21

Most Recent Stories

More News
Verrica (VRCA) Down 64% as Molluscum Drug Gets CRL From FDA

Verrica Pharmaceuticals' (VRCA) new drug application for VP-102 to treat molluscum contagiosum faces rejection from the FDA for a second time.

ALKS : 30.54 (+4.02%)
ANGN : 1.5000 (+13.64%)
ABEO : 0.1680 (+9.02%)
VRCA : 2.00 (+2.30%)
Aerie (AERI) Starts Late-Stage Study to Treat Dry Eye Disease

Aerie Pharmaceutials (AERI) doses the first patient in a phase III study on its investigational TRMP8 agonist drug for the treatment of dry eye disease.

ALKS : 30.54 (+4.02%)
ANGN : 1.5000 (+13.64%)
AERI : 5.42 (-0.18%)
ABEO : 0.1680 (+9.02%)
Athersys (ATHX) Down as Ischemic Stroke Study Fails to Meet Goal

While a mid-stage/late-stage study evaluating Athersys' (ATHX) stem cell treatment for ischemic stroke misses out on its primary endpoint, top-line data shows evidence of therapeutic impact.

ALKS : 30.54 (+4.02%)
ANGN : 1.5000 (+13.64%)
ATHX : 0.2108 (+9.22%)
ABEO : 0.1680 (+9.02%)
Enanta's (ENTA) RSV Drug Fails to Meet Study Goal, Stock Drops

While a mid-stage study evaluating Enanta's (ENTA) RSV candidate misses out on its primary endpoint, a statistically huge number of subjects achieved undetectable RSV RNA at the end of treatment.

PFE : 53.91 (-0.15%)
ALKS : 30.54 (+4.02%)
ENTA : 39.47 (+3.51%)
ABEO : 0.1680 (+9.02%)
Abeona Therapeutics Granted Second 180-Day Period by Nasdaq to Regain Compliance with Minimum Bid Price Rule

NEW YORK and CLEVELAND, May 19, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy,...

ABEO : 0.1680 (+9.02%)
AVROBIO (AVRO) Stock Up on Upbeat Data From Cystinosis Study

Results from AVROBIO's (AVRO) phase I/II study, which is evaluating its gene-therapy candidate for cystinosis, show the latter's potential to stabilize or reduce the impact of cystinosis on different tissues....

ALKS : 30.54 (+4.02%)
ANGN : 1.5000 (+13.64%)
ABEO : 0.1680 (+9.02%)
AVRO : 0.9600 (+5.76%)
Ultragenyx (RARE) Acquires Rights of AAV Gene Therapy Candidate

Ultragenyx (RARE) signs an exclusive license agreement with Abeona Therapeutics to acquire the latter's gene therapy candidate, ABO-102 (now UX111), for treating Sanfilippo syndrome type A.

RARE : 48.64 (+6.11%)
ABEO : 0.1680 (+9.02%)
AGLE : 1.5700 (+1.29%)
APLT : 1.5400 (+8.45%)
Philips' (PHG) Launches a Range of New Products at EuroPCR 2022

Philips' (PHG) launches innovative new solutions to attract customers amid a global supply crunch and drive top-line growth.

PHG : 25.54 (+0.24%)
AMN : 95.63 (+2.01%)
ABEO : 0.1680 (+9.02%)
ACRS : 13.00 (+4.25%)
AbbVie (ABBV) Buys Option Rights to NextGen Inflammation Drug

AbbVie (ABBV) receives the option to license worldwide rights for certain IL-2 muteins, including the next-generation inflammatory candidate, CUG252 from Cugene

ALKS : 30.54 (+4.02%)
ABBV : 150.00 (-0.38%)
ABEO : 0.1680 (+9.02%)
SESN : 0.5300 (+1.47%)
Abeona Therapeutics Reports First Quarter 2022 Financial Results

Disposition of MPS programs to reduce operating expenses and extend projected cash runway into 2Q 2023 Focus R&D resources on EB-101 pivotal phase 3...

ABEO : 0.1680 (+9.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products for rare diseases. Abeona Therapeutics Inc., formerly known as PlasmaTech Biopharmaceuticals, Inc., is based in Dallas, United States.

See More

Key Turning Points

3rd Resistance Point 0.1953
2nd Resistance Point 0.1827
1st Resistance Point 0.1753
Last Price 0.1680
1st Support Level 0.1553
2nd Support Level 0.1427
3rd Support Level 0.1353

See More

52-Week High 1.9200
Fibonacci 61.8% 1.2363
Fibonacci 50% 1.0251
Fibonacci 38.2% 0.8140
Last Price 0.1680
52-Week Low 0.1303

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar